ADIL · Adial Pharmaceuticals, Inc. · Metrics
$4.86
-0.35 (-6.72%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$13.13M
Shares
2.63M
ADIL metrics
43 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$5.21
Market cap
$13.13M
Price action
20 metricsPrice change (1W)
-11.6%
Price change (30D)
-3.9%
Price change (3M)
+90.5%
Price change (6M)
+208.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
112.9%
Annualized volatility (3M)
109.8%
Beta
0.7
RSI (14D)
49.2
Price vs SMA 50
+19.0%
Price vs SMA 200
—
Avg volume (3M)
69,599
Relative volume
0.4
Average dollar volume
$278,956
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
2.63M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-440.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2022-11-15
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$57.68M
Net income (TTM)
−$57.80M
Trailing 12 months
Diluted EPS (TTM)
$-11.53
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+987.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-198.7%
Debt / equity
—
Current ratio
5.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$28.71M
Latest balance sheet
Cash & equivalents
$28.71M
Total assets
$29.09M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$11.13M
Capital expenditures (TTM)
$64,605
R&D (TTM)
$2.01M
SG&A (TTM)
—
Stock compensation (TTM)
$600,200
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
17
13F filer change QoQ
+2
Institutional ownership
5.2%
Short interest
3 metricsShort interest
9.3%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
78 / 100
Insider activity
2 metricsNet insider buying (90D)
$106,329
Insider-sentiment score
85 / 100
Risk flags
1 metricsGoing concern
Flagged